Key result
Doravirine-based regimens show no change in 10-year ASCVD risk scores in people with HIV.
Why the study?
Does a doravirine-based HIV treatment regimen prevent increases in ASCVD risk scores in people living with HIV?
RCT (n=369)
Open-label
randomized
Does a doravirine-based HIV treatment regimen prevent increases in ASCVD risk scores in people living with HIV?
Answers are grounded in this paper and cite their sources.
Doravirine-based antiretroviral therapy does not increase 10-year ASCVD risk scores over 4 years of follow-up in people living with HIV, offering a cardiovascular-safe treatment option.
BACKGROUND: People living with HIV (PLWH) on antiretroviral therapy have an increased risk of atherosclerotic cardiovascular disease (ASCVD). Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor, has a favorable lipid profile, minimal effect on weight, and is not expected to impact ASCVD risk. We evaluated the impact of DOR on ASCVD risk in PLWH in 2 phase 3 trials. SETTING: Post hoc analysis of DRIVE-FORWARD (NCT02275780) and DRIVE AHEAD (NCT02403674). METHODS: Participants were randomized to DOR + 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) or ritonavir-boosted darunavir + 2 NRTIs (DRIVE-FORWARD) or to DOR/lamivudine/tenofovir or efavirenz/emtricitabine/tenofovir (DRIVE-AHEAD) for 96 weeks. Participants could continue or switch to the DOR-based regimen in 96-week open-label extensions. The 10-year ASCVD risk was calculated at baseline and weeks 24, 48, 96, and 192. RESULTS: The 369 participants included 60.4% White men, 19.0% Black/African American men, 11.7% Black/African American women, and 8.9% White women. Baseline characteristics were generally comparable across the subgroups and trials. A slight trend toward increased ASCVD risk scores for men was observed at week 192. This increase was not observed when the analysis used age at baseline as a fixed value instead of natural age at each study visit, suggesting that age rather than DOR might have caused the increase in ASCVD risk scores in the male population. CONCLUSIONS: After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH. Given the increased burden of HIV-associated ASCVD, DOR may represent a therapeutic option that does not increase ASCVD risk.
No takes yet. Share an insight, caveat, or question.
Hsue et al. (2025) conducted an RCT in HIV (n=369). Doravirine-based regimen vs. Ritonavir-boosted darunavir + 2 NRTIs or efavirenz/emtricitabine/tenofovir was evaluated on 10-year ASCVD risk score. In 369 people living with HIV, doravirine-based regimens for up to 192 weeks were not associated with changes in 10-year ASCVD risk scores.
Synapse has enriched 10 related papers. Consider them for comparative context: